Menu
← Oncology Approval Tracker
FDA DECISION ·
Nubeqa
darolutamide · Bayer Healthcare Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with metastatic castration-sensitive prostate cancer receiving androgen deprivation, without a requirement for docetaxel.
LAMPGEN ANALYSIS
Why it matters
The indication allows darolutamide plus androgen deprivation without the chemotherapy required in the previous metastatic castration-sensitive indication.
What research teams should watch
Record whether androgen deprivation is pharmacologic or surgical and assess how a non-docetaxel regimen affects patient visits.
PRIMARY RECORDS